Although all cancers are molecularly distinct, many share common driver mutations.1 Pan-cancer profiling can provide useful insights into frequently mutated genes, regardless of tumor origin. Using next-generation sequencing (NGS), pan-tumor projects such as The Cancer Genome Atlas2 have made significant contributions to our understanding of DNA and RNA variants across many cancer types.
Targeted sequencing is the simplest and most cost-effective method for pan-cancer profiling. Expert-defined gene panels eliminate the need to isolate gene targets of NGS separately, and multiplexing enables many samples to be run at the same time regardless of tumor type. Multiplexing enables pan-cancer RNA studies to be run in parallel with DNA studies for a comprehensive tumor profile.
Pan-cancer profiling using NGS follows a simple workflow that can be easily scaled to hundreds of samples. Clinical research labs can go from DNA to report in approximately 40 hours. This workflow uses a single instrument, minimizing steps and integrating seamlessly into the lab setting. Pan-cancer profiling allows the inclusion of markers from various cancer types in a single assay, positively impacting workflows and turnaround times.
Illumina products empower clinical cancer researchers to use the most current technologies to find accurate answers while seamlessly integrating NGS into their labs. A comprehensive portfolio of cancer-specific library preparation kits enables labs to run DNA and RNA assays simultaneously for a broad view of tumor mechanisms.
Illumina sequencers deliver industry-leading accuracy, generating ~90% of the world’s sequencing data.* Efficient reporting capabilities enable researchers to annotate, classify, and communicate significant findings in a standard format that facilitates data analyses and trending.
Click on the below to view products for each workflow step.
The TruSight Oncology UMI Reagents and UMI Error Correction App reduce error rates in samples to ≤0.007%, enabling the detection of low frequency variants.TruSight RNA Pan-Cancer
Targeting 1385 oncology genes for gene expression, variant and fusion detection in all RNA sample types including FFPE.AmpliSeq for Illumina Cancer HotSpot Panel v2
Targeted research panel investigating hotspot regions of 50 genes with known associations to cancer.
A gene fusion detection panel targeting fusion associated genes in many cancer types with the ability to detect known and novel fusion gene partners.
Simplest and most affordable solution for low-throughput targeted sequencing for pan-cancer profiling.MiSeq System
Desktop sequencer featuring a simple NGS workflow, integrated data analysis software, and unmatched accuracy.
Easy-to-use software for analysis and variant calling on the MiSeq System.VariantStudio Software
A powerful analysis and reporting tool that provides biological insight into genomic variant data.
* Data calculations on file. Illumina, Inc. 2015.